CXCR4 and myocardial infarction: Compared to treatment with vehicle, the sequential treatment with the β3-AR agonist mirabegron and the CXCR4 antagonist AMD3100 (MA treatment) led to significant increase in circulating MSCs at day 5 post myocardial infarction.